PubMed Journals Articles About "Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings" - Page: 20 RSS

13:24 EDT 20th October 2018 | BioPortfolio

Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings articles that have been published worldwide.

More Information about "Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings" on BioPortfolio

We have published hundreds of Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings news stories on BioPortfolio along with dozens of Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings Clinical Trials and PubMed Articles about Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings Companies in our database. You can also find out about relevant Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings Drugs and Medications on this site too.

Showing "Cytori Therapeutics CYTX Marc Hedrick 2017 Results Earnings" PubMed Articles 476–500 of 41,000+

Table: drugs for ulcerative colitis.

Drugs for inflammatory bowel disease.

Reassessing Coronary Artery Bypass Surgery Versus Percutaneous Coronary Intervention in Patients with Type 2 Diabetes Mellitus: A Brief Updated Analytical Report (2015-2017).

In this analysis, we aimed to systematically compare percutaneous coronary intervention (PCI) versus coronary artery bypass surgery (CABG) in terms of adverse outcomes utilizing data from a recent (2015-2017) population of patients with type 2 diabetes mellitus (T2DM).

Correction: p53 and metabolism: from mechanism to therapeutics.

[This corrects the article DOI: 10.18632/oncotarget.25267.].

Corrections of Equations on Glycemic Variability and Quality of Glycemic Control.

Comparison table: some FDA-approved drugs for weight management.

Diet, drugs, devices, and surgery for weight management.

Comparison table: some drugs for inflammatory bowel disease.

Loss of profilin 2 contributes to enhanced epithelial-mesenchymal transition and metastasis of colorectal cancer.

Profilin 2 (PFN2) functions as an actin cytoskeleton regulator and serves an important role in cell motility. However, a role for PFN2 in the progression of colorectal cancer (CRC), particularly in metastasis, has yet to be clarified. The aim of the present study was to investigate whether PFN2 served specific roles in the progression of human CRC. The results demonstrated that PFN2 was differentially expressed in CRC tissues and cell lines by reverse transcription-quantitative polymerase chain reaction an...

Antitumor Effect of Calcium-Mediated Destabilization of Epithelial Growth Factor Receptor on Non-Small Cell Lung Carcinoma.

Despite the development of numerous therapeutics targeting the epithelial growth factor receptor (EGFR) for non-small cell lung carcinoma (NSCLC), the application of these drugs is limited because of drug resistance. Here, we investigated the antitumor effect of calcium-mediated degradation of EGFR pathway-associated proteins on NSCLC. First, lactate calcium salt (LCS) was utilized for calcium supplementation. Src, α-tubulin and EGFR levels were measured after LSC treatment, and the proteins were visualize...

Time-series analysis of tuberculosis from 2005 to 2017 in China.

Seasonal autoregressive integrated moving average (SARIMA) has been used to model nationwide tuberculosis (TB) incidence in other countries. This study aimed to characterise monthly TB notification rate in China. Monthly TB notification rate from 2005 to 2017 was used. Time-series analysis was based on a SARIMA model and a hybrid model of SARIMA-generalised regression neural network (GRNN) model. A decreasing trend (3.17% per years, P < 0.01) and seasonal variation of TB notification rate were found from 20...

Vital Signs: Prevalence of Key Cardiovascular Disease Risk Factors for Million Hearts 2022 - United States, 2011-2016.

Despite decades-long reductions in cardiovascular disease (CVD) mortality, CVD mortality rates have recently plateaued and even increased in some subgroups, and the prevalence of CVD risk factors remains high. Million Hearts 2022, a 5-year initiative, was launched in 2017 to address this burden. This report establishes a baseline for the CVD risk factors targeted for reduction by the initiative during 2017-2021 and highlights recent changes over time.

Response to: "The Role of Quantitative Systems Pharmacology in the Design of First-in-Human Trials".

COPD 2017: A Year in Review.

In this review, we focused on original manuscripts published in the 2017 that provided additional information on the clinical and therapeutic features of the chronic obstructive pulmonary disease (COPD). We have chosen eight of these studies, collected in four topics concerning the pharmacological treatment (tiotropium) of mild-moderate patients, the pharmacological (fluticasone furoate/vilanterol/umeclidinium) and non-pharmacological treatment (non-invasive mechanical ventilation) of severe patients, the e...

Drugs for rheumatoid arthritis.

ISMB/ECCB 2017 proceedings.

A Salute to Our Reviewers 2017.

Ralph Salisbury 1938-2017.

Boyd Parkinson 1927-2017.

Hypertension management options: 2017 guideline.

John E. McDermott, MD (1931-2017).

Invited Readers 2017.

In Memoriam: John Edward Kalsbeck, MD (1928-2017).

Beni Solow award 2017.

Salute to Our Reviewers-2017-2018.

Quick Search